Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 9, 2014The Journal of ArthroplastyOpen Access

Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does edoxaban prevent thromboembolic events in patients undergoing total hip arthroplasty compared to enoxaparin?

Population

264 patients undergoing total hip arthroplasty (THA) in Japan and Taiwan

Comparison

Edoxaban 15 mg or 30 mg oral once daily for… vs Enoxaparin 2000 IU twice daily for 11-14 days

Design

RCT, randomly received

Follow-up

11-14 days

Authors

TFTakeshi FujiOsaka HospitalCWC.-J. WangKaohsiung Medical UniversitySFShinya� FujitaTokyo Medical and Dental University

Discussion

Loading...

Member takes

Implication

Edoxaban matches enoxaparin for post-THA VTE prevention; confirms once-daily oral option in this RCT.

Structured PICO

Does edoxaban prevent thromboembolic events in patients undergoing total hip arthroplasty compared to enoxaparin?

P
Population
264 patients undergoing total hip arthroplasty (THA) in Japan and Taiwan
I
Intervention
Edoxaban 15 mg or 30 mg oral once daily for 11-14 days
C
Comparator
Enoxaparin 2000 IU (20 mg) twice daily for 11-14 days
O
Outcome
Thromboembolic event incidencescomposite

Once-daily edoxaban showed similar efficacy and safety to enoxaparin for the prevention of thromboembolic events in patients undergoing total hip arthroplasty.

Cite This Study

Fuji et al. (2014) studied this question.

synapsesocial.com/papers/6a804d85d82d8273d046f8abhttps://doi.org/10.1016/j.arth.2014.05.029
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement2010 · 147 citations
  2. 2Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism2013 · 1,884 citations
  3. 3Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers2010 · 454 citations
  4. 4Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects2013 · 154 citations
  5. 5Edoxaban versus Warfarin in Patients with Atrial Fibrillation2013 · 5,199 citations